Advertisement

Pain management: pharmacological approaches

  • Russell K. Portenoy
  • Gerri Frager
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 100)

Abstract

More than three quarters of patients with advanced cancer experience chronic pain that is severe enough to warrant therapy with opioid drugs [1,2]. The most prevalent pain syndromes are disease related in adults and treatment related in children [3,4]. In adults with metastatic solid tumors, disease-related pains are usually persistent and often progressive, a pattern that reflects the limited availability of effective primary therapies for many of these tumors. In the pediatric population, the availability of effective antineoplastic therapies for the common tumors yields a pattern of disease-related pain that is typically characterized by transitory episodes [5].

Keywords

Neuropathic Pain Cancer Pain Postherpetic Neuralgia Painful Diabetic Neuropathy Opioid Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Portenoy RK. 1989. Cancer pain — epidemiology and syndromes. Cancer 63:2298–2307.PubMedCrossRefGoogle Scholar
  2. 2.
    Bonica JJ. 1990. Cancer pain. In Bonica JJ (ed), the Management of Pain, 2nd ed. Philadelphia: Lea and Febiger, 400–414.Google Scholar
  3. 3.
    McGrath PJ, Hsu E, Cappelli M, et al. 1990. Pain from pediatric cancer: a survey of an outpatient oncology clinic. J Psychosoc Oncol 8:109–124.CrossRefGoogle Scholar
  4. 4.
    Miser AW, Dothage JA, Wesley RA, et al. 1987. The prevalence of pain in a pediatric and young adult cancer population. Pain 29:73–83.PubMedCrossRefGoogle Scholar
  5. 5.
    Miser AW, MCalla J. Dothage JA, Wesley M, Miser JS. 1987. Pain as a presenting symptom in children and young adults with newly diagnosed malignancy. Pain 29:85–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Foley KM. 1993. Pain assessment and cancer pain syndromes. In Doyle D, Hanks GW, MacDonald RN (eds), Oxford Textbook of Palliative Medicine. Oxford: Oxford Medical Publications, 148–165.Google Scholar
  7. 7.
    Fitzgerald M, Anand KJS. 1993. Developmental neuroanatomy and neurophysiology of pain. In Schechter NL, Berde CB, Yaster M (eds), Pain in Infants, Children, and Adolescents. Baltimore: Williams and Wilkins, 11–31Google Scholar
  8. 8.
    World Health Organization. 1996. Cancer Pain Relief, 2nd ed. Geneva: World Health Organization.Google Scholar
  9. 9.
    American Pain Society. 1992. Principles of Analgesic Use in the Treatment of Acute Pain and Chronic Cancer Pain, 3rd ed. Skokie, IL: American Pain Society.Google Scholar
  10. 10.
    Ventafridda V. 1987. A validation study of the WHO method for cancer pain relief. Cancer 59:851–856.CrossRefGoogle Scholar
  11. 11.
    Walker VA. 1988. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. JPSM 3:145–149.Google Scholar
  12. 12.
    Jorgensen L. 1990. Treatment of cancer pain patients in a multidisciplinary pain clinic. Pain Clin 3:83–89.Google Scholar
  13. 13.
    Schug SA, Zech D, Ground S, et al. 1992. A long-term survey of morphine in cancer pain patients. JPSM 7:258–266.Google Scholar
  14. 14.
    Ventafridda V, Ripamonti C, De Conno F, Tamburini M, Cassileth BR. 1990. Symptom prevalence and control during cancer patients’ last days of life. J Palliat Care 6(3):7–11PubMedGoogle Scholar
  15. 15.
    Fainsinger R, Miller MJ, Bruera E, Hanson J, Maceachern T. 1991 Symptom control during the last week of life on a palliative care unit. J Palliat Care 7(1):5–11Google Scholar
  16. 16.
    Higginson I, McCarty M. 1989. Measuring symptoms in terminal cancer: are pain and dyspnea controlled? J R Soc Med 82(5):264–267.PubMedGoogle Scholar
  17. 17.
    Vane JR. 1971 Inhibition of prostaglandia synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 234:231Google Scholar
  18. 18.
    Insel PA. 1990. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In Gilman AG, Rall TW, Nies AS, Taylor P (eds), The Pharmacological Basis of Therapeutics, 8th ed. New York: Permagon Press, 638.Google Scholar
  19. 19.
    Ballinger A. 1994. Cytoprotection with misoprostol: use in the treatment and prevention of ulcers. Dig Dis 12:37.PubMedCrossRefGoogle Scholar
  20. 20.
    Powell H, Smallman JM, Morgan M. 1990. Comparison of intramuscular ketorolac and morphine in pain control after laparotomy. Anaesthesia 45:538.PubMedCrossRefGoogle Scholar
  21. 21.
    Power I, Noble DW, Douglas E, et al. 1990. Comparison of IM ketorolac tromethamine and morphine sulphate for pain relief after cholecystectomy. Br J Anaesth 65:448.PubMedCrossRefGoogle Scholar
  22. 22.
    Houde RW. 1979. Analgesic effectiveness of narcotic agonist-antagonists. Br J Clin Pharmacol 7:297.CrossRefGoogle Scholar
  23. 23.
    Agency for Health Care Policy and Research Acute Pain Management Panel. 1992. Acute Pain Management Operative or Medical Procedures and Trauma. Washington, D.C.: U.S. Department of Health and Human Services.Google Scholar
  24. 24.
    Szeto HH, Inturrisi CE, Houde R, et al. 1977. Accumulation of normeperidine an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 86:738.PubMedGoogle Scholar
  25. 25.
    Eisendrath SJ, Goldman B, Douglas J, et al. 1987. Meperidine-induced delirium. Am J Psychiatry 144:1062.PubMedGoogle Scholar
  26. 26.
    Hagmeyer KO, Mauro LS, Mauro VF. 1993. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother 27:29.PubMedGoogle Scholar
  27. 27.
    Kaiko RF. 1986. Commentary: Equianalgesic dose ratio of intramuscular/oral morphine, 1:6 versus 1:3. In Foley KM, Inturrisi CE (eds), Opioid Analgesics in the Management of Clinical Pain. Advances Pain Research and Therapy, vol. 8. New York: Raven Press, 87.Google Scholar
  28. 28.
    Twycross RG. 1988. Opioid analgesics in cancer pain: current practice and controversies. Cancer Surv 7:29.PubMedGoogle Scholar
  29. 29.
    Houde RW, Wallenstein SL, Beaver WT. 1965. Clinical measurement of pain. In de Stevens G (ed), Analgesics. New York: Academic Press, 75.Google Scholar
  30. 30.
    Sjogren P. In press. Clinical implications of morphine metabolites. In Portenoy RK, Bruera EB (eds), Supportive Care Medicine, vol. 1 New York: Oxford University Press.Google Scholar
  31. 31.
    Paul D, Standifer KM, Inturrisi CE, et al. 1989. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 251:477.PubMedGoogle Scholar
  32. 32.
    Osborne RJ, Joel SP, Slevin ML. 1986. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br J Med 292:1548.CrossRefGoogle Scholar
  33. 33.
    Hanna MH, Peat SJ, Woodham M, et al. 1990. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 64:547.PubMedCrossRefGoogle Scholar
  34. 34.
    Osborne R, Thompson P, Joel S, et al. 1992. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 34:130.PubMedCrossRefGoogle Scholar
  35. 35.
    Portenoy RK, Thaler HT, Inturrisi CE, et al. 1992. The metabolite, morphine-6-glucuronide, contributes to the analgesia produced by morphine infusion in pain patients with normal renal function. Clin Pharmacol Ther 51:422.PubMedCrossRefGoogle Scholar
  36. 36.
    D’Honneur G, Gilton A, Sandouk P, et al. 1994. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 81:87.CrossRefGoogle Scholar
  37. 37.
    Hagen N, Foley KM, Cerbone DJ, et al. 1991 Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 6:125.PubMedCrossRefGoogle Scholar
  38. 38.
    Lehmann KA, Zech D. 1993. Morphine-6-glucuronide, a pharmacologically active morphine metabolite: a review of the literature. Eur J Pain 12:28.Google Scholar
  39. 39.
    Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T. 1991 Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 35:642.PubMedCrossRefGoogle Scholar
  40. 40.
    Kalso E, Vainio A. 1990. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 5:639.CrossRefGoogle Scholar
  41. 41.
    Calis KA, Kohler DR, Corso DM. 1992. Transdermally administered fentanyl for pain management. Clin Pharmacol 11:22.Google Scholar
  42. 42.
    Fine PG, Marcus M, De Boer AJ, et al. 1991 An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 45:149.PubMedCrossRefGoogle Scholar
  43. 43.
    Sinatra RS, Hyde NH, Harrison DM. 1988. Oxymorphone revisited. Semin Anesth 8:208.Google Scholar
  44. 44.
    Hermens JM, Hanifin JM, Hirshman CA. 1985. Comparison of histamine release in human skin mast cells by morphine, fentanyl and oxymorphone. Anesthesiology 62:124.PubMedCrossRefGoogle Scholar
  45. 45.
    Fainsinger R, Schoeller T, Bruera E. 1993. Methadone in the management of cancer pain: a review. Pain 52:137.PubMedCrossRefGoogle Scholar
  46. 46.
    Sawe J, Hansen J, Ginman C, et al. 1981 Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J 282:771CrossRefGoogle Scholar
  47. 47.
    Wallenstein SL, Rogers AG, Kaiko RF. 1986. Clinical analgesic studies of levorphanol in acute and chronic cancer pain. In Foley KM, Inturrisi CE (eds), Opioid Analgesics in the Management of Clinical Pain. Advances in Pain Research and Therapy, vol. 8. New York: Raven Press, 211Google Scholar
  48. 48.
    Coyle N, Cherny NI, Portenoy RK. 1994. Subcutaneous opioid infusions in the home. Oncology 8:21PubMedGoogle Scholar
  49. 49.
    Bruera E, Brenneis C, Michaud M, et al. 1988. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 62:407.PubMedCrossRefGoogle Scholar
  50. 50.
    Storey P, Hill HH, St. Louis R, et al. 1990. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 5:33.PubMedCrossRefGoogle Scholar
  51. 51.
    Portenoy RK. 1987. Continuous intravenous infusions of opioid drugs. Med Clin North Am 71:233.PubMedGoogle Scholar
  52. 52.
    Dover SB. 1987. Syringe driver in terminal care. Br Med J 294:553.CrossRefGoogle Scholar
  53. 53.
    Amesbury BDW. 1989. Use of SC Midazolam in the home care setting. Palliat Med 3:299.CrossRefGoogle Scholar
  54. 54.
    Oliver DJ. 1988. Syringe drivers in palliative care: a review. Palliat Med 2:21CrossRefGoogle Scholar
  55. 55.
    Trissel LA, Xu Q, Martinez JF, et al. 1994. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22, and 32°C. Am J Hosp Pharm 51:2138.PubMedGoogle Scholar
  56. 56.
    Swarm RA, Cousins MJ. 1993. Anaesthetic techniques for pain control. In Doyle D, Hanks GWC, MacDonald RN (eds), Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 204.Google Scholar
  57. 57.
    Portenoy RK, Hagen NA. 1990. Breakthrough pain: definition, prevalence and characteristics. Pain 41:273–282.PubMedCrossRefGoogle Scholar
  58. 58.
    Sykes NP. 1991 Oral naloxone in opioid associated constipation. Lancet 337:1475.PubMedCrossRefGoogle Scholar
  59. 59.
    Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. 1992. Treatment of opioid induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 52:90.PubMedCrossRefGoogle Scholar
  60. 60.
    Allan SG. 1993. Nausea and vomiting. In Doyle D, Hanks GWC, MacDonald RN (eds), Oxford Textbook of Palliative Medicine. Oxford: Oxford University Press, 282.Google Scholar
  61. 61.
    Bruera E, Macmillan K, Hanson J, et al. 1989. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 39:13.PubMedCrossRefGoogle Scholar
  62. 62.
    Eisele JH, Grigsby EJ, Dea G. 1992. Clonazepam treatment of myoclonic contractions associated with high dose opioids: a case report. Pain 49:231PubMedCrossRefGoogle Scholar
  63. 63.
    Portenoy RK. 1994. Tolerance to opioid analgesics: clinical aspects. In Hanks GWC (ed), Palliative Medicine: Problem Areas in Pain and Symptom Management. Plainview, NY: Cold Spring Harbor Press, 49.Google Scholar
  64. 64.
    Foley KM. 1991 Clinical tolerance to opioids. In Basbaum AI, Besson JM (eds), Towards a New Pharmacotherapy of Pain. Chichester: John Wiley & Sons, 181Google Scholar
  65. 65.
    Kanner RM, Foley KM. 1981 Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci 362:161PubMedCrossRefGoogle Scholar
  66. 66.
    Coyle N, Breitbart W, Weaver S, et al. 1994. Delirium as a contributing factor to ‘crecendo’ pain: three case reports. J Pain Symptom Manage 9:44.PubMedCrossRefGoogle Scholar
  67. 67.
    Kanner RM, Foley KM. 1981 Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci 362:161–172.PubMedCrossRefGoogle Scholar
  68. 68.
    Medina JL, Diamond S. 1977. Drug dependency in patients with chronic headache. Headache 17:12.PubMedCrossRefGoogle Scholar
  69. 69.
    Morrison RA. 1991 Update on sickle cell disease: incidence of addiction and choice of opioid in pain management. Pediatr Nurs 10:7–8.Google Scholar
  70. 70.
    Perry S, Heidrich G. 1982. Management of pain during debridement: a survey of U.S. burn units. Pain 13:267.PubMedCrossRefGoogle Scholar
  71. 71.
    Porter J, Hick H. 1980. Addiction rare in patients treated with narcotics. N Eng J Med 302:123.Google Scholar
  72. 72.
    Weissman DE, Haddox JD. 1989. Opioid pseudoaddiction — an iatrogenic syndrome. Pain 36:363.PubMedCrossRefGoogle Scholar
  73. 73.
    Portenoy RK. 1991 Issues in the management of neuropathic pain. In Basbaum AI, Besson J-M (eds), Towards a New Pharmacotherapy of Pain. Chichester: John Wiley & Sons, 393–416.Google Scholar
  74. 74.
    Portenoy RK, Foley KM, Inturrisi CE. 1990. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 43:273–286.PubMedCrossRefGoogle Scholar
  75. 75.
    Portenoy RK. 1993. Adjuvant analgesics in pain management. In Doyle D, Hanks GWC, MacDonald N (eds), Oxford Textbook of Palliative Medicine. Oxford: Oxford Medical Publications, 187–203.Google Scholar
  76. 76.
    Max MB, Culnane M, Schafer SC, et al. 1987. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 37:589–594.PubMedCrossRefGoogle Scholar
  77. 77.
    Kishore-Kumar R, Max MB, Schafer SC, et al. 1990. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 47:305–312.PubMedCrossRefGoogle Scholar
  78. 78.
    Watson CPN, Chipman M, Reed K, Evans RJ, Birkett N. 1992. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain 48:29–36.PubMedCrossRefGoogle Scholar
  79. 79.
    Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. 1990. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42:135–144.PubMedCrossRefGoogle Scholar
  80. 80.
    Davidoff G, Guarracini M, Roth E, Sliwa J, Yarkony G. 1987. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain 29:151–161PubMedCrossRefGoogle Scholar
  81. 81.
    Dejgard A, Petersen P, Kastrup J. 1988. Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 1:9–11PubMedCrossRefGoogle Scholar
  82. 82.
    Lindstrom P, Lindblom U. 1987. The analgesic effect of tocainide in trigeminal neuralgia. Pain 28:45–50.PubMedCrossRefGoogle Scholar
  83. 83.
    Galer BS, Miller KV, Rowbotham MC. 1993. Response to intravenous lidocaine differs based on clinical diagnosis and site of nervous system injury. Neurology 43:1233–1245.PubMedCrossRefGoogle Scholar
  84. 84.
    Kreeger W, Hammill SC. 1987. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone. Mayo Clin Proc 62:1033–1050.PubMedGoogle Scholar
  85. 85.
    Swerdlow M. 1984. Anticonvulsant drugs and chronic pain. Clin Neuropharmacol 7:51–82.PubMedCrossRefGoogle Scholar
  86. 86.
    Fromm GH, Terence CR, Chatta AS. 1984. Baclofen in the treatment of trigeminal neuralgia. Ann Neurol 15:240–247.PubMedCrossRefGoogle Scholar
  87. 87.
    Lechin F, van der Dijs B, Lechin ME, et al. 1989. Pimozide therapy for trigeminal neuralgia. Arch Neurol 9:960–962.CrossRefGoogle Scholar
  88. 88.
    Rowbotham MC. 1994. Topical analgesic agents. In Fields HJL, Liebeskind JC (eds), Pharmacological Approaches to the Treatment of Chronic Pain: New Concepts and Critical Issues. Seattle, WA: IASP Press, 211–228.Google Scholar
  89. 89.
    Watson CPN, Evans RJ, Watt VR. 1988. Postherpetic neuralgia and topical capsaicin. Pain 33:333–340.PubMedCrossRefGoogle Scholar
  90. 90.
    Watson CPN, Evans RJ, Watt VR. 1989. The post-mastectomy pain syndrome and the effect of topical capsaicin. Pain 38:177–186.PubMedCrossRefGoogle Scholar
  91. 91.
    Capsaicin Study Group. 1991 Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 151(11): 2225–2229.CrossRefGoogle Scholar
  92. 92.
    Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. 1992. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 15(1):8–14.PubMedCrossRefGoogle Scholar
  93. 93.
    Ehrenstrom GME, Reiz SLA. 1982. EMLA — a eutectic mixture of local anesthetics for topical anesthesia. Acta Anaesthesiol Scand 26:596–598.CrossRefGoogle Scholar
  94. 94.
    Rowbotham MC, Davies PS, Fields HL. 1995. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 37:246–253.PubMedCrossRefGoogle Scholar
  95. 95.
    Stow PJ, Glynn CJ, Minor B. 1989. EMLA cream in the treatment of post herpetic neuralgia: efficacy and pharmacokinetic profile. Pain 39:301–305.PubMedCrossRefGoogle Scholar
  96. 96.
    Eisenach JC, Dewan DM, Rose JC, Angelo JM. 1987. Epidural Clonidine produces antinociception, but not hypotension, in sheep. Anesthesiology 66:496–501PubMedCrossRefGoogle Scholar
  97. 97.
    Max MB, Schafer SC, Culnane, et al. 1988. Association of pain relief with drug side effects in postherpetic neuralgia: a single dose study of Clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 43:363–371PubMedCrossRefGoogle Scholar
  98. 98.
    Tan Y-M, Croese J. 1986. Clonidine and diabetic patients with leg pains. Ann Intern Med 105:633–634.PubMedGoogle Scholar
  99. 99.
    Patt RB, Proper G, Reddy S. 1994. Neuroleptics as adjuvant analgesics. J Pain Symptom Manage 9:446–453.PubMedCrossRefGoogle Scholar
  100. 100.
    Beaver WT, Wallenstein SM, Houde RW, Rogers A. 1966. A comparison of the analgesic effects of methotrimeprazine and morphine in patients with cancer. Clin Pharmacol Ther 7:436–446.PubMedGoogle Scholar
  101. 101.
    Fernandez F, Adams F, Holmes VF 1987. Analgesic effect of alprazolam in patients with chronic, organic pain of malignant origin. J Clin Psychopharmacol 7:167–169.PubMedCrossRefGoogle Scholar
  102. 102.
    Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. 1985. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754.PubMedGoogle Scholar
  103. 103.
    Delia Cuna GR, Pellegrini A, Piazzi M. 1989. Effect of methylprednisolone sodium succinate on qauality of life in preterminal cancer patients. A placebo-controlled multicenter study. Eur J Cancer Clin Oncol 25:1817–1821CrossRefGoogle Scholar
  104. 104.
    Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, Rider W. 1989. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597.PubMedGoogle Scholar
  105. 105.
    Ettinger AB, Portenoy RK. 1988. The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3:99–103.PubMedCrossRefGoogle Scholar
  106. 106.
    Hanks GW, Trueman T, Twycross RG. 1983. Corticosteroids in terminal cancer. Postgrad Med J 59:702–706.PubMedCrossRefGoogle Scholar
  107. 107.
    Greenberg HS, Kim J, Posner JB. 1980. Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 8:361–366.PubMedCrossRefGoogle Scholar
  108. 108.
    Gobelet C, Waldburger M, Meier JL. 1992. The effect of adding calcitonin to physical treatment on reflex sympathetic dystrophy. Pain 48:171–175.PubMedCrossRefGoogle Scholar
  109. 109.
    Jaeger H, Maier C. 1992. Calcitonin in phantom limb pain: a double blind study. Pain 48:21–27.PubMedCrossRefGoogle Scholar
  110. 110.
    Woolf CJ, Thompson SWN. 1991 The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation: implications for the treatment of post-injury pain hypersensitivity states. Pain 44:293–299.PubMedCrossRefGoogle Scholar
  111. 111.
    Dickenson AH, Sullivan AF 1987. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep dorsal horn nociceptive neurons followingg C fibre stimulation. Neuropharmacology 26:1235–1238.PubMedCrossRefGoogle Scholar
  112. 112.
    Price DD, Mao J, Frenk H, Mayer DJ. 1994. The N-methyl-D-aspartate antagonist dextromethorphan selectively reduces temporal summation of second pain in man. Pain 59:165–174.PubMedCrossRefGoogle Scholar
  113. 113.
    Park KM, Max MB, Robinovitz E, Gracely RH, Bennett GJ. 1994. Effects of intravenous ketamine and alfentanil on hyperalgesia induced by intradermal capsaicin. In Gebhardt GF, Hammond DL, Jensen TS (eds), Proceedings of the 7th World Congress on Pain. Seattle: IASP Press, 647–655.Google Scholar
  114. 114.
    McQuay HJ, Carrol D, Jadad AR, Glynn CJ, Jack T, Moore RA, Wiffen PJ. 1994. Dextromethorphan for the treatment of neuropathic pain: a double-blind, randomised controlled crossover trial with integral n-of-1 design. Pain 59:127–134.PubMedCrossRefGoogle Scholar
  115. 115.
    Backonja M, Arndt G, Gombar KA, Check B, Zimmerman M. 1994. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 56:51–57.PubMedCrossRefGoogle Scholar
  116. 116.
    Persson J, Axelsson G, Hallin RG, Gustafsson LL. 1995. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 60:217–222.PubMedCrossRefGoogle Scholar
  117. 117.
    Nielson OS, Munro AJ, Tannock IF. 1991 Bone metastases: pathophysiology and management policy. J Clin Oncol 9(3):509–524.Google Scholar
  118. 118.
    Rosier R. 1993. Orthopedic management of cancer pain. In Patt RB (ed), Cancer Pain. Philadelphia: J.B. Lippincott, 467.Google Scholar
  119. 119.
    Coleman RE, Wo UPJ, Miles M, et al. 1988. Treatment of bone metastases from breast cancer with (3 amino-l-hydroxypropylidene)-l,l-bisphosphonate (APD). Br J Cancer 58:621–625.PubMedCrossRefGoogle Scholar
  120. 120.
    Thiebaud D, Leyvraz S, von Fliedner V, et al. 1991 Treatment of bone metastases from breast cancer and myeloma with Pamidronate. Eur J Cancer 27:37–41PubMedCrossRefGoogle Scholar
  121. 121.
    van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, et al. 1993. Palliative Pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491–498.PubMedGoogle Scholar
  122. 122.
    Ernst DS, Mac Donald RN, Paterson AH, et al. 1992. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Manage 7:4–11PubMedCrossRefGoogle Scholar
  123. 123.
    Roth A, Kolaric K. 1986. Analgesic activity of calcitonin in patient with painful osteolytic metastases of breast cancer: results of a controlled randomized study. Oncology 43:283–287.PubMedCrossRefGoogle Scholar
  124. 124.
    Warrell RP, Lovett D, Dilmanian FA, et al. 1993. Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 11:2443–2450.PubMedGoogle Scholar
  125. 125.
    Porter AT, EcEwan AJ, Powe JE, et al. 1993. Results of a randomized phase-Ill trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805–813.PubMedCrossRefGoogle Scholar
  126. 126.
    Averbuch SD. 1993. New bisphosphonates in the treatment of bone metastases. Cancer Supp 72(11):3433–3452.Google Scholar
  127. 127.
    van Holten-Verzantvoort ATM, Bijvoet OLM, Cleton FJ, et al. 1987. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 297:772–773.Google Scholar
  128. 128.
    Paterson AHG, Powles TJ, Kanis JA, et al. 1993. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11(l):59–65.PubMedGoogle Scholar
  129. 129.
    Glover D, Lipton A, Keller A, et al. 1994. Intravenous Pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 74(11):2949–2955.PubMedCrossRefGoogle Scholar
  130. 130.
    Robinson RG, Preston DF, Baxter KG. 1993. Clinical experience with strontium-89 in prostatic and breast cancer patients. Semin Oncol 20(3):44–48.PubMedGoogle Scholar
  131. 131.
    Robinson RG, Preston DF, Spicer JA, et al. 1992. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 22(l):28–32.PubMedGoogle Scholar
  132. 132.
    Katin MJ, Dosoretz DE, Blitzer PH, et al. 1994. Using strontium-89 to control bone pain. Contemp Oncol 23–31Google Scholar
  133. 133.
    Porter AT, Davis LP. 1994. Systemic radionuclide therapy of bone metastases with strontium-89. Oncology 8(2):93–101PubMedGoogle Scholar
  134. 134.
    Ripamonti C. 1994. Management of bowel obstruction in advanced cancer patients. J Pain Symptom Manage 9:193–200.PubMedCrossRefGoogle Scholar
  135. 135.
    Baines M, Oliver DJ, Carter RL. 1985. Medical management of intestinal obstruction in patients with advanced malignant disease: a clinical and pathological study. Lancet 2:990–993.PubMedCrossRefGoogle Scholar
  136. 136.
    Ventafridda V, Ripamonti C, Caraceni A, Spoldi E, Messina L, De Conno F. 1990. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 76:389–393.PubMedGoogle Scholar
  137. 137.
    De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. 1991 Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 6:484–486.PubMedCrossRefGoogle Scholar
  138. 138.
    Mercadante S, Maddaloni S. 1992. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage 7:496–498.PubMedCrossRefGoogle Scholar
  139. 139.
    Fainsinger RL, Spachynski K, Hanson J, Bruera E. 1994. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage 9:12–18.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Russell K. Portenoy
  • Gerri Frager

There are no affiliations available

Personalised recommendations